Cargando…
Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor. Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure...
Autores principales: | Zeng, Xiaoyu, Liu, Lin, Zheng, Mengzhu, Sun, Huimin, Xiao, Juanjuan, Lu, Tao, Huang, Guangqian, Chen, Pianpian, Zhang, Jianmin, Zhu, Feng, Li, Hua, Duan, Qiuhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008373/ https://www.ncbi.nlm.nih.gov/pubmed/26967058 http://dx.doi.org/10.18632/oncotarget.7984 |
Ejemplares similares
-
Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase
por: Zheng, Mengzhu, et al.
Publicado: (2017) -
Pantoprazole, a proton pump inhibitor, increases orthodontic tooth movement in rats
por: Shirazi, Mohsen, et al.
Publicado: (2014) -
Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice
por: Vegger, J.B., et al.
Publicado: (2017) -
Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver
por: Assalin, Heloisa B., et al.
Publicado: (2022) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)